Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

56.77 (USD) • At close October 17, 2024
Bedrijfsnaam Ultragenyx Pharmaceutical Inc.
Symbool RARE
Munteenheid USD
Prijs 56.77
Beurswaarde 5,232,218,404
Dividendpercentage 0%
52-weken bereik 31.52 - 60.37
Industrie Biotechnology
Sector Healthcare
CEO Dr. Emil D. Kakkis M.D., Ph.D.
Website https://www.ultragenyx.com

An error occurred while fetching data.

Over Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked

Vergelijkbare Aandelen

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

20.98 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

43.47 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

54.53 USD

Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

BPMC

86 USD

CureVac N.V. logo

CureVac N.V.

CVAC

2.82 USD

Karuna Therapeutics, Inc. logo

Karuna Therapeutics, Inc.

KRTX

329.83 USD

Patterson Companies, Inc. logo

Patterson Companies, Inc.

PDCO

21.1 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)